Loading...
Market
How will Brenus Pharma's stock price change within one week of announcing Phase 1 clinical trial results?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Stock market data from financial news outlets or stock exchanges
Story
Brenus Pharma Raises €22.2 Million ($25 Million) to Advance Cancer Vaccine Trials
Sep 19, 2024, 08:13 AM
Brenus Pharma, a French biotech company based in Lyon, has successfully raised €22.2 million ($25 million) in a Series A funding round. The funds will be used to accelerate the clinical trials of its precision cancer vaccines. The funding round was led by Angelor, a prominent investment firm. Brenus Pharma specializes in developing innovative cancer vaccines aimed at improving patient outcomes.
View original story
Similar markets
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Changes by less than 10% • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%